Lonafarnib (1 brand name, 1 dosage form, 1 route)
Available dosage forms: CAPSULE.
Routes of administration: ORAL.
Brand Names
- ZOKINVY
Indications and Usage
ZOKINVY is indicated in patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above: To reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS) For the treatment of processing-deficient Progeroid Laminopathies with either: Heterozygous LMNA mutation with progerin-like protein accumulation Homozygous or compound heterozygous ZMPSTE24 mutations
Contraindications
ZOKINVY is contraindicated in patients taking: Strong CYP3A inhibitors [see Drug Interactions (7.1)] Strong or moderate CYP3A inducers [see Drug Interactions (7.1)] Midazolam [see Drug Interactions (7.2)] Lovastatin, simvastatin, or atorvastatin [see Drug Interactions (7.2)]
Mechanism of Action
Lonafarnib inhibits farnesyltransferase to prevent farnesylation and subsequent accumulation of progerin and progerin-like proteins in the inner nuclear membrane.